Rain Oncology Future Growth
Future criteria checks 0/6
Rain Oncology is forecast to grow earnings at 23.3% per annum. EPS is expected to grow by 26.9% per annum.
Key information
23.3%
Earnings growth rate
26.9%
EPS growth rate
| Pharmaceuticals earnings growth | 19.8% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 03 Jan 2024 |
Recent future growth updates
Recent updates
Is Rain Oncology (NASDAQ:RAIN) In A Good Position To Invest In Growth?
Feb 23
We Think Rain Therapeutics (NASDAQ:RAIN) Needs To Drive Business Growth Carefully
Nov 08Rain Therapeutics GAAP EPS of -$0.66 in-line
Aug 04Here's Why We're Watching Rain Therapeutics' (NASDAQ:RAIN) Cash Burn Situation
Aug 03We're Not Very Worried About Rain Therapeutics' (NASDAQ:RAIN) Cash Burn Rate
Apr 17We Think Rain Therapeutics (NASDAQ:RAIN) Can Afford To Drive Business Growth
Dec 25We're Hopeful That Rain Therapeutics (NASDAQ:RAIN) Will Use Its Cash Wisely
Sep 21Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -30 | N/A | N/A | 1 |
| 12/31/2025 | N/A | -26 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -46 | N/A | N/A | 2 |
| 12/31/2023 | N/A | -64 | N/A | N/A | 2 |
| 9/30/2023 | N/A | -72 | -68 | -66 | N/A |
| 6/30/2023 | N/A | -83 | -74 | -74 | N/A |
| 3/31/2023 | N/A | -79 | -68 | -68 | N/A |
| 12/31/2022 | N/A | -76 | -63 | -63 | N/A |
| 9/30/2022 | N/A | -71 | -60 | -60 | N/A |
| 6/30/2022 | N/A | -71 | -59 | -56 | N/A |
| 3/31/2022 | N/A | -62 | -52 | -50 | N/A |
| 12/31/2021 | N/A | -51 | -40 | -37 | N/A |
| 9/30/2021 | N/A | -39 | -35 | -32 | N/A |
| 6/30/2021 | N/A | -31 | -28 | -23 | N/A |
| 3/31/2021 | N/A | -25 | -19 | -14 | N/A |
| 12/31/2020 | N/A | -21 | -16 | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RAIN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RAIN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RAIN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if RAIN's revenue is forecast to grow faster than the US market.
High Growth Revenue: RAIN is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RAIN's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/26 04:47 |
| End of Day Share Price | 2024/01/26 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rain Oncology Inc. is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yigal Nochomovitz | Citigroup Inc |
| Charles Butler | D. Boral Capital LLC. |
| Michael Schmidt | Guggenheim Securities, LLC |